Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

Diabetologia
M NauckB Willms

Abstract

Intravenous glucagon-like peptide (GLP)-1 [7-36 amide] can normalize plasma glucose in non-insulin-dependent diabetic (NIDDM) patients. Since this is no form for routine therapeutic administration, effects of subcutaneous GLP-1 at a high dose (1.5 nmol/kg body weight) were examined. Three groups of 8, 9 and 7 patients (61 +/- 7, 61 +/- 9, 50 +/- 11 years; BMI 29.5 +/- 2.5, 26.1 +/- 2.3, 28.0 +/- 4.2 kg/m2; HbA1c 11.3 +/- 1.5, 9.9 +/- 1.0, 10.6 +/- 0.7%) were examined: after a single subcutaneous injection of 1.5 nmol/kg GLP [7-36 amide]; after repeated subcutaneous injections (0 and 120 min) in fasting patients; after a single, subcutaneous injection 30 min before a liquid test meal (amino acids 8%, and sucrose 50 g in 400 ml), all compared with a placebo. Glucose (glucose oxidase), insulin, C-peptide, GLP-1 and glucagon (specific immunoassays) were measured. Gastric emptying was assessed with the indicator-dilution method and phenol red. Repeated measures ANOVA was used for statistical analysis. GLP-1 injection led to a short-lived increment in GLP-1 concentrations (peak at 30-60 min, then return to basal levels after 90-120 min). Each GLP-1 injection stimulated insulin (insulin, C-peptide, p < 0.0001, respectively) and inhibi...Continue Reading

Citations

Dec 7, 2002·Diabetes/metabolism Research and Reviews·Jens Juul Holst
Dec 20, 2011·Pharmaceutical Research·Yanguang CaoWilliam J Jusko
Dec 20, 2003·Bioorganic & Medicinal Chemistry Letters·Emma R ParmeeAnn E Weber
May 15, 2002·European Journal of Pharmacology·Juris J MeierMichael A Nauck
Sep 17, 2002·European Journal of Pharmacology·Ulla RibelLotte Bjerre Knudsen
Oct 6, 1997·Endocrinology and Metabolism Clinics of North America·H E Lebovitz
Jun 7, 2003·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Henrik Agersø, Paolo Vicini
Mar 10, 2004·The British Journal of Nutrition·Erik NäslundP M Hellström
Jun 28, 2006·Diabetes Technology & Therapeutics·David M KendallDavid Maggs
Jul 8, 2011·Diabetes Technology & Therapeutics·Anthony StonehouseRobert Cuddihy
Oct 1, 2010·Diabetes, Obesity & Metabolism·E E WrightR M Cuddihy
Feb 3, 1999·Annals of the New York Academy of Sciences·J J HolstL Bjerre-Knudsen
Jun 15, 2004·Gut·P G Kopelman, C Grace
Jul 22, 2009·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum
Oct 29, 2010·Critical Care : the Official Journal of the Critical Care Forum·Adam M DeaneMichael Horowitz
Jan 25, 2011·Critical Care : the Official Journal of the Critical Care Forum·Adam M DeaneMichael Horowitz
Jul 17, 2008·The Journal of Clinical Endocrinology and Metabolism·Chee W Chia, Josephine M Egan
May 12, 2007·The Review of Diabetic Studies : RDS·Baptist Gallwitz
Jul 25, 2012·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Helen BerlieNicole R Pinelli
May 14, 2009·Vascular Health and Risk Management·Carolyn F Deacon
Dec 2, 2005·Treatments in Endocrinology·Baptist Gallwitz
Mar 19, 2003·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Juris J MeierMichael A Nauck
Jul 10, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Tina Vilsbøll, Filip K Knop
Jul 23, 2013·Journal of Clinical Biochemistry and Nutrition·Shinobu MatsumotoNaoto Nakamura
May 7, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jeremy PettusSteven Edelman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.